CBEA-BCannabielsoic acid B
The acidic isomer of cannabielsoin with a carboxyl at position 4, a marker of acidic CBD oxidation.
C₂₂H₃₀O₅
CAS 55652-62-5
- Family
- PhytocannabinoidMinor
- Origin
- Degradation product
- Molar mass
- 374.50 g/mol
Updated on
In plain terms
Cannabielsoic acid B is one of the two acidic isomers of cannabielsoin, formed by oxidation of acidic CBD (CBDA). It was isolated from hashish in 1974. Its own pharmacology has never been measured.
Receptors and activity
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of CBEA-B, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Cannabielsoic acid B is the positional isomer of cannabielsoic acid A: the same dibenzofuran nucleus, formed by closing a furan ring on the cannabidiol skeleton, but with the carboxyl at position 4 of the aromatic nucleus instead of position 2. Shani and Mechoulam isolated it from hashish in 1974, in the work that established the structure of the cannabielsoic acids and their formation by oxidative cyclisation. It is an oxidation product of cannabidiolic acid; its decarboxylation gives cannabielsoin. Among the acids of the family, it is the only one for which a propyl homologue (CBEA-C3 B) has been described. No affinity for CB1 or CB2 has been measured for the acid form; only neutral cannabielsoin has pharmacological data (Haghdoost 2024). No animal or human data exist.
Key sources.
- Shani & Mechoulam 1974, Tetrahedron 30:2437-2446: cannabielsoic acids, isolation from hashish and synthesis by oxidative cyclisation (new tab)DOI 10.1016/S0040-4020(01)97114-5
- Haghdoost et al. 2024, Biomedicines: cannabielsoin, a CBD oxidation product, biased CB1 agonist (new tab)PMID 39062125
- Yamamoto et al. 1991, Pharmacol Biochem Behav: cannabielsoin, a CBD metabolite in mammals (new tab)PMID 1806944
- Gul et al. 2023, Planta Med: validated GC-FID method for 20 cannabinoids (including CBEA) (new tab)PMID 36257598
- ElSohly & Slade 2005, Life Sci: CBE-type cannabinoids (CBEA-C5 A and B, CBEA-C3 B) (new tab)PMID 16199061
- Radwan et al. 2021, Molecules: inventory of cannabis cannabinoids (CBE type, five compounds) (new tab)PMID 34066753
- PubChem CID 59444401: cannabielsoic acid B (new tab)
History
- Source
- Present in cannabis (hashish) as an oxidation product of cannabidiolic acid (CBDA).
Biosynthetic pathway
No enzyme is known. Cannabielsoic acids form by oxidative cyclisation of CBDA, which closes a furan ring and gives the family's dibenzofuran nucleus; here the carboxyl occupies position 4 of the aromatic nucleus, the only difference from isomer A. Decarboxylation leads to cannabielsoin.
Legal framework
- European Union
No EU instrument specific to the molecule; not named in the schedules of the 1961 and 1971 United Nations conventions.
- France
Not classified as a narcotic: cannabielsoic acid B is not named in the ANSM consolidated list (updated 26/06/2026). Its dibenzofuran nucleus is not the benzo[c]chromene nucleus of the generic class (ANSM decisions of 22/05/2024 and 03/06/2024), and it is not a tetrahydrocannabinol within the entry « Tétrahydrocannabinols, leurs esters, éthers, sels » (annex III since the ANSM decision of 06/02/2026). Not being a narcotic is not, in itself, an authorisation to sell. Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Phytocannabinoid › Minor
- Presence in the plant
Artefact: formed by oxidation, light, heat or solvent
- Chemistry
Type CBE · C5 side chain · acid form
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
No dedicated article.
References
- Shani & Mechoulam 1974, Tetrahedron 30:2437-2446: cannabielsoic acids, isolation from hashish and synthesis by oxidative cyclisation (new tab)DOI 10.1016/S0040-4020(01)97114-5
- Haghdoost et al. 2024, Biomedicines: cannabielsoin, a CBD oxidation product, biased CB1 agonist (new tab)PMID 39062125
- Yamamoto et al. 1991, Pharmacol Biochem Behav: cannabielsoin, a CBD metabolite in mammals (new tab)PMID 1806944
- Gul et al. 2023, Planta Med: validated GC-FID method for 20 cannabinoids (including CBEA) (new tab)PMID 36257598
- ElSohly & Slade 2005, Life Sci: CBE-type cannabinoids (CBEA-C5 A and B, CBEA-C3 B) (new tab)PMID 16199061
- Radwan et al. 2021, Molecules: inventory of cannabis cannabinoids (CBE type, five compounds) (new tab)PMID 34066753
- PubChem CID 59444401: cannabielsoic acid B (new tab)
Identifiers
Names
- Common name
- Cannabielsoic acid B
- IUPAC name
- (5aS,6S,9R,9aR)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5aH-dibenzofuran-4-carboxylic acid
- Other names
- CBEA-C5 B · CBEA-B
Identifiers
- Formula
- C₂₂H₃₀O₅
- CAS
- 55652-62-5
- PubChem CID
- 59444401(new tab)
- InChIKey
- HJMCQDCJBFTRPX-RSGMMRJUSA-N
- SMILES
- CCCCCC1=
CC(= C2[C@H] 3[C@@H] (CC[C@] ([C@H] 3OC2= C1C(= O) O) (C) O) C(= C) C) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.